CONTEXT: Normal glucose homeostasis is maintained despite reductions in insulin sensitivity by increasing insulin secretion. This ability to compensate for reduced insulin sensitivity is highly heritable, but the mechanisms for this compensation or its failure in type 2 diabetes (T2DM) are unknown. OBJECTIVE: The objective of this study was to test whether individuals with a family history of T2DM have a fixed decrease in beta-cell mass or function that would be revealed as an impaired insulin secretory response to short-term insulin resistance. DESIGN: Glucose tolerance, insulin sensitivity (S(I)), and insulin response to i.v. glucose (AIR(G)) were compared in nondiabetic individuals with and without a family history of diabetes before and after nicotinic acid (NA) treatment. SETTING: This study was performed at the Ambulatory General Clinical Research Center. SUBJECTS: Healthy, nonobese, nondiabetic individuals with or without a family history of T2DM were studied. INTERVENTIONS: Oral NA was given, with a final dose of 2 g/d, for at least 7 d. MAIN OUTCOME MEASURE: The main outcome measure was the disposition index (insulin sensitivity x insulin response) in response to NA. RESULTS: Postchallenge plasma glucose levels rose during NA therapy regardless of family history. Neither group adequately increased their AIR(G) to maintain the disposition index. Family members did not differ from controls at baseline or after NA treatment for any outcome measure, but only 28 of 52 subjects experienced a 25% or greater fall in S(I) with NA treatment. CONCLUSIONS: Short-term beta-cell compensation to NA-induced insulin resistance was incomplete and did not differ by genetic predisposition. A genetic defect controlling beta-cell growth in response to chronic insulin resistance better explains differences in the ability to compensate for insulin resistance than an inherited, fixed defect in beta-cell mass.
CONTEXT: Normal glucose homeostasis is maintained despite reductions in insulin sensitivity by increasing insulin secretion. This ability to compensate for reduced insulin sensitivity is highly heritable, but the mechanisms for this compensation or its failure in type 2 diabetes (T2DM) are unknown. OBJECTIVE: The objective of this study was to test whether individuals with a family history of T2DM have a fixed decrease in beta-cell mass or function that would be revealed as an impaired insulin secretory response to short-term insulin resistance. DESIGN:Glucose tolerance, insulin sensitivity (S(I)), and insulin response to i.v. glucose (AIR(G)) were compared in nondiabetic individuals with and without a family history of diabetes before and after nicotinic acid (NA) treatment. SETTING: This study was performed at the Ambulatory General Clinical Research Center. SUBJECTS: Healthy, nonobese, nondiabetic individuals with or without a family history of T2DM were studied. INTERVENTIONS: Oral NA was given, with a final dose of 2 g/d, for at least 7 d. MAIN OUTCOME MEASURE: The main outcome measure was the disposition index (insulin sensitivity x insulin response) in response to NA. RESULTS: Postchallenge plasma glucose levels rose during NA therapy regardless of family history. Neither group adequately increased their AIR(G) to maintain the disposition index. Family members did not differ from controls at baseline or after NA treatment for any outcome measure, but only 28 of 52 subjects experienced a 25% or greater fall in S(I) with NA treatment. CONCLUSIONS: Short-term beta-cell compensation to NA-induced insulin resistance was incomplete and did not differ by genetic predisposition. A genetic defect controlling beta-cell growth in response to chronic insulin resistance better explains differences in the ability to compensate for insulin resistance than an inherited, fixed defect in beta-cell mass.
Authors: S C Elbein; W S Chu; S K Das; A Yao-Borengasser; S J Hasstedt; H Wang; N Rasouli; P A Kern Journal: Diabetologia Date: 2007-06-20 Impact factor: 10.122
Authors: John R Guyton; Sergio Fazio; Adeniyi J Adewale; Erin Jensen; Joanne E Tomassini; Arvind Shah; Andrew M Tershakovec Journal: Diabetes Care Date: 2012-02-14 Impact factor: 19.112
Authors: Muckta Khan; Robert Ringseis; Frank-Christoph Mooren; Karsten Krüger; Erika Most; Klaus Eder Journal: BMC Vet Res Date: 2013-09-09 Impact factor: 2.741